Epigral Q2FY27: Revenue surges 28% to ₹752 Cr, PAT up 26% to ₹64 Cr
Epigral's Q2FY27 revenue surged 28% to ₹752 Crore and PAT grew 26% to ₹64 Crore. H1FY27 revenue rose 21% to ₹1,461 Crore, with PAT up 25% to ₹164 Crore. The company is investing in capacity expansions, with Epoxy Resin & Formulations and MPP projects slated for H2FY28 commissioning. CPVC and ECH capacity enhancements are expected within a quarter.
The announcement includes significant financial performance metrics (revenue and profit growth) and details about ongoing and upcoming capacity expansions, which are material to investors and the company's future outlook.
The company reported strong double-digit growth in revenue and profit for both Q2FY27 and H1FY27, indicating a positive financial performance. Expansion plans are progressing as scheduled, suggesting future growth potential.
Epigral Limited announced its Un-Audited Financial Results for the second quarter of FY27, reporting a significant year-on-year revenue growth of 28%, reaching ₹752 Crore. This growth was driven by a 6% increase in sales volume and improved realisations, despite challenging market conditions. The Derivatives & Specialty business contributed 57% to the revenue, up from 50% in the same quarter last year. EBITDA saw a marginal increase of 3% to ₹136 Crore, with EBITDA margins at 18% impacted by high raw material costs. Profit After Tax (PAT) grew by 26% to ₹64 Crore from ₹51 Crore in Q2FY26.
For the half-year ended September 30, 2026 (H1FY27), revenue increased by 21% to ₹1,461 Crore, while EBITDA grew by 7% to ₹315 Crore, maintaining an EBITDA margin of 22%. PAT for H1FY27 rose by 25% to ₹164 Crore. The company's Net Debt to EBITDA ratio stood at 0.9x as of September 30, 2026.
Epigral also provided updates on its capital expenditure plans. The company spent ₹88 Crore on capex in H1FY27. Two major projects, an Epoxy Resin & Formulations plant (1,25,000 TPA) and a Multi-Purpose Plant (MPP) for Epichlorohydrin (ECH) and Chlorotoluene Value Chain, are expected to be commissioned by H2FY28. Additionally, capex for enhancing CPVC Resin and ECH capacities, along with a Wind Solar Hybrid Power Plant, are in the final stages of project completion and are anticipated to be commissioned within a quarter.
Chairman and Managing Director, Mr. Maulik Patel, expressed optimism, stating, "Despite a challenging operating environment in Q2FY27, we achieved revenue growth of 28%, driven by volume growth and improved realisations. Elevated raw material prices had its impact on EBITDA margins; however, our H1FY27 performance remained resilient, with revenue growth of 21% and an EBITDA margin of 22%. With the second half of the fiscal traditionally delivering stronger performance than the first, we maintain positive outlook for H2FY27." He further highlighted the execution of expansion plans on schedule, with CPVC and ECH expansions nearing commissioning.
What to do with a filing like this
Epigral Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Epigral Limited. Read the original for the full detail.